These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 5041298)

  • 1. [Use of 2 preparations of factor IX concentrate in the treatment of a patient with hemophilia B].
    den Ottolander GJ
    Ned Tijdschr Geneeskd; 1972 Jul; 116(30):1278-82. PubMed ID: 5041298
    [No Abstract]   [Full Text] [Related]  

  • 2. [A factor IX-concentrate for the treatment of haemophilia B].
    Suomela H; Myllylä G
    Duodecim; 1971; 87(1):31-8. PubMed ID: 5539580
    [No Abstract]   [Full Text] [Related]  

  • 3. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and clinical use of factor IX concentrate PPSB according to Soulier.
    Haanen C; McShine RL; Kunst A
    Vox Sang; 1969 Apr; 16(4):398-411. PubMed ID: 5800593
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of hemophilia B with a new clotting-factor concentrate.
    Hoag MS; Johnson FF; Robinson JA; Aggeler PM
    N Engl J Med; 1969 Mar; 280(11):581-6. PubMed ID: 5764825
    [No Abstract]   [Full Text] [Related]  

  • 6. Recombinant factor IX for the treatment of hemophilia B. Introduction.
    Thompson A
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):1-3. PubMed ID: 9565159
    [No Abstract]   [Full Text] [Related]  

  • 7. [Non-activated and activated prothrombin complex concentrates, Proplex and Feiba, in the treatment of a hemophilia B patient with high titer inhibitor against factor IX].
    Niiya K; Hirose S; Taguchi H; Miyoshi I
    Rinsho Ketsueki; 1985 Jun; 26(6):980-4. PubMed ID: 3877825
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B.
    Shapiro AD; Ragni MV; Lusher JM; Culbert S; Koerper MA; Bergman GE; Hannan MM
    Thromb Haemost; 1996 Jan; 75(1):30-5. PubMed ID: 8713776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.
    Aledort LM
    Haemophilia; 2010 Jul; 16 Suppl 6():1-2. PubMed ID: 20561350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial infarction during factor IX infusion in hemophilia B: case report and review of the literature.
    Najaf SM; Malik A; Quraishi AU; Kazmi K; Kakepoto GN
    Ann Hematol; 2004 Sep; 83(9):604-7. PubMed ID: 15205916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune tolerance induction for a patient with factor IX inhibitors--a case report.
    Nagel K; Laudenbach L; Rivard GE; Jardine L; Chan AK; Pai MK
    Haemophilia; 2011 Mar; 17(2):315. PubMed ID: 20825499
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant factor IX.
    White GC; Beebe A; Nielsen B
    Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A safe approach to treatment of factor IX-deficient patients. Introduction and overview of treatment.
    Aledort LM
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):1-2. PubMed ID: 1780765
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B.
    Djulbegovic B; Marasa M; Pesto A; Kushner GM; Hadley T; Joseph G; Goldsmith G
    Am J Hematol; 1996 Feb; 51(2):168-70. PubMed ID: 8579061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of severe haemophilia B with a factor IX concentrate (author's transl)].
    Ludwig E; Lechner K
    Dtsch Med Wochenschr; 1974 Jun; 99(25):1355-61. PubMed ID: 4836072
    [No Abstract]   [Full Text] [Related]  

  • 16. Multiple extractions in hemophilia B--use of a PTC (factor IX) concentrate: report of case.
    Kline SN; Lewis JH; Bayer WL; Kahn MR
    J Oral Surg; 1970 Apr; 28(4):292-4. PubMed ID: 5309178
    [No Abstract]   [Full Text] [Related]  

  • 17. [Preparation and clinical use of a new factor IX concentrate].
    Lopaciuk S; Poszwiński P
    Acta Haematol Pol; 1978; 9(2):107-12. PubMed ID: 665130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombogenicity associated with factor IX complex concentrates.
    Lusher JM
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):3-5. PubMed ID: 1780767
    [No Abstract]   [Full Text] [Related]  

  • 19. Prophylaxis in children with hemophilia: is it the optimal treatment?
    Lusher JM
    Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
    [No Abstract]   [Full Text] [Related]  

  • 20. Improvements in factor concentrates.
    Lillicrap D
    Curr Opin Hematol; 2010 Sep; 17(5):393-7. PubMed ID: 20613509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.